StockWatch
·

Biofrontera Inc. Q1 FY26 Results

BFRIQ1 FY26 Results
Filing
MetricValue ($ M)Q1 FY25
Revenue10.0817.4%
Total Income10.0817.4%
Expenditure14.409.6%
PBT-4.7513.1%
Net Profit-4.7513.1%
OPM-42.84%10.11pp
NPM-47.12%1.82pp
EPS-0.4112.8%
View full financials

Biofrontera Inc. Reports Q1 2026 Revenue of $10.1 Million, Up 17% YoY

14 May 2026 · 14 May, 5:36 pm

Summary

Biofrontera Inc. reported a 17% increase in revenue for Q1 2026, reaching $10.1 million compared to $8.6 million in Q1 2025. Gross margins significantly improved to approximately 80%, up from 62% in the prior year. The company's operating loss was $4.3 million, slightly better than the $4.5 million loss in Q1 2025. Biofrontera is advancing its clinical pipeline, with the FDA accepting the filing of its sNDA for Ameluz® PDT and positive Phase 3 results in AK on neck/trunk and extremities.

Key Highlights

  1. 1

    Biofrontera Inc. reported revenues for Q1 2026 of $10.1 million, a ~17% increase compared to $8.6 million for the same period in 2025.

  2. 2

    Gross margins were approximately 80% in Q1 2026, an 18 percentage points increase compared to approximately 62% in Q1 2025.

  3. 3

    The operating loss was $4.3 million in Q1 2026, compared to a loss of $4.5 million in Q1 2025.

  4. 4

    Adjusted EBITDA improved to $(3.6) million from $(4.4) million in Q1 2025, reflecting expanded gross margins.

  5. 5

    The company largely maintained its operating cash balance, with $6.3 million as of March 31, 2026, compared to $1.8 million in Q1 2025.

  6. 6

    FDA accepted the filing of the company’s supplemental New Drug Application (sNDA) for Ameluz® PDT for the treatment of superficial basal cell carcinoma (sBCC), with a PDUFA target action date of September 28, 2026.

  7. 7

    Positive top-line results were announced from its Phase 3 clinical trial evaluating Ameluz® PDT for the treatment of mild to moderate actinic keratoses (AKs) on the extremities, neck, and trunk.

Management Comments

H

Hermann Luebbert

“The first quarter of 2026 marks the first full quarter under our new cost structure following the Strategic Transaction, and the results speak clearly. Revenue grew 17% year over year, gross margins expanded to approximately 80%, and our cash consumption was near zero—a dramatic improvement from $4.1 million of cash consumption in the prior-year quarter. Our results were further driven by continued commercial momentum leading to significant uptake of the Ameluz PDT platform by dermatologists and their patients. At the same time, our clinical pipeline continues to advance at an accelerated pace. With a PDUFA date for sBCC in September 2026, positive Phase 3 results in AK on neck/trunk and extremities, and encouraging Phase 2b data in acne, we have multiple near-term catalysts that could meaningfully expand the commercial opportunity for the Ameluz platform. We remain focused on our goal of reaching sustained profitability and cash-flow breakeven while setting the foundation for medium to long-term growth, and I believe we are well positioned to help our customers and their patients and build long-term value for our shareholders.”

Informational and educational content only. Not investment advice.